NEW YORK, Oct. 2, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ('Baird Medical' or the 'Company'), a leading microwave ablation ('MWA') medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ('ExcelFin') (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the 'Business Combination'). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ('PubCo'), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols 'BDMD' and 'BDMDW', respectively, on October 2, 2024.

On September 26, 2024, ExcelFin held a special meeting of its stockholders (the 'Special Meeting') to consider and vote upon a proposal to approve the Business Combination described in the proxy statement/prospectus. At the Special Meeting, in person or by proxy, the holders of 6,015,236 shares of ExcelFin's Class A common stock, constituting 91.36% of the issued and outstanding voting capital stock of ExcelFin entitled to vote, were present at the Special Meeting. Approximately 99.9% of the votes cast at the Special Meeting were in favor of approving the Business Combination. Complete official results of the vote are included in a current report on Form 8-K filed by ExcelFin with the U.S. Securities and Exchange Commission (the 'SEC').